Last updated on April 2018

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects


Brief description of study

This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects with hypertriglyceridemia.

Detailed Study Description

The study will consist a Screening Phase (up to 4 months) followed by a Treatment Phase (12 weeks), and a Follow-up visit (within 1 week after the last dose). A total of 40 male and female subjects 18 years of age are planned to be enrolled. During the Screening Phase, subjects will be assessed for study eligibility. After signing the informed consent form, the following assessments will be performed: medical history including review of prior and current medications, physical examination including height and body weight, waist circumference, vital signs and an electrocardiogram. Clinical labs, routine chemistries, hematology, coagulation profile, urinalysis and a serum pregnancy test will be collected as well as cytokeratin-18 (CK-18), a biomarker for NASH diagnosis. An alcohol consumption questionnaire will be administered and a MRI scan of the liver will be performed. Serum fibrosis markers, the Fib-4 index (age, AST, ALT, PLT) and NAFLD fibrosis score (age, BMI, AST/ALT ratio, IFG/DM, PLT, Albumin) will be calculated.

Clinical Study Identifier: NCT02681055

Contact Investigators or Research Sites near you

Start Over

Julio A Gutierrez, MD

Southern California Research Center
Coronado, CA United States
  Connect »

MediciNova Research Coordinator

Scripps Clinic
La Jolla, CA United States
  Connect »

Charles S Landis, MD, PhD

Harborview Medical Center
Seattle, WA United States
  Connect »